IBS007125

IBS007125 inhibits c-Maf transcriptional activity in HEK293T cells, as measured by reduced Ccl8 promoter-driven luciferase activity^[1].
IBS007125 (18 h pre-incubation before LPS stimulation; 24 h LPS stimulation) selectively suppresses c-Maf-dependent cytokine (CCL8, IL-10) production without affecting c-Maf-independent TNFα production in LPS-stimulated BMDMs^[1].
IBS007125 (0-20 μM; 5 days) suppresses proliferation of c-Maf-expressing RPMI-8226 multiple myeloma cells in a dose-dependent manner but does not affect proliferation of c-Maf-negative U266 multiple myeloma cells^[1].
IBS007125 (10 μM; 2 days for c-Maf mRNA; 3 days for ITGB7 and CCR1 mRNA) modestly reduces c-Maf mRNA expression and significantly represses expression of the c-Maf target genes ITGB7 and CCR1 in RPMI-8226 multiple myeloma cells^[1].
IBS007125 (10 μM; 2 days) does not affect c-Maf protein levels or post-translational modifications (as indicated by unaltered molecular weight) in RPMI-8226 multiple myeloma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.